Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zachary F Zimmerman

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cold Spring Harbor Perspectives in Biology|September 25, 2012
Targeting Wnt pathways in diseaseZachary F Zimmerman, Randall T Moon, Andy J Chien
Plos One|July 23, 2013
Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trailZachary F Zimmerman, Rima M Kulikauskas, Karol Bomsztyk, et al.
Journal of Medical Economics|June 21, 2017
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspectiveThomas E Delea, Jordan Amdahl, Diana Boyko, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug AdministrationAndrew D J Pearson, Elly Barry, Yael P Mossé, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cold Spring Harbor Perspectives in Biology|September 25, 2012
Targeting Wnt pathways in diseaseZachary F Zimmerman, Randall T Moon, Andy J Chien
Plos One|July 23, 2013
Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trailZachary F Zimmerman, Rima M Kulikauskas, Karol Bomsztyk, et al.
Journal of Medical Economics|June 21, 2017
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspectiveThomas E Delea, Jordan Amdahl, Diana Boyko, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug AdministrationAndrew D J Pearson, Elly Barry, Yael P Mossé, et al.
Pageof 1